Omega Diagnostics Group PLC (GB:CNSL)
LSE:CNSL
CNSL Stock Chart & Stats
2.30 p
-0.05 p(-1.67%)
At close: 4:00 PM EST
2.30 p
-0.05 p(-1.67%)
Day’s Range― - ―
52-Week Range1.70 p - 4.33 p
Previous CloseN/A
Volume6.91K
Average Volume (3M)353.57K
Market Cap
£4.40M
Enterprise Value1.05M
Total Cash (Recent Filing)£3.59M
Total Debt (Recent Filing)£237.00K
Price to Earnings (P/E)―
Beta0.96
Next Earnings
Jul 29, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.00
Shares Outstanding237,950,650
10 Day Avg. Volume111,535
30 Day Avg. Volume353,573
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.64
Price to Sales (P/S)0.87
P/FCF Ratio-51.18
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthVery low leverage and a mid-teens ROE provide durable financial flexibility. Low debt reduces bankruptcy risk and preserves capacity to fund working capital, R&D or selective M&A without stressing the capital structure, supporting resilience across economic cycles.
High Gross & Net MarginsStrong gross and net margins indicate pricing power or efficient manufacturing for core IVD products. Durable high gross margin supports long-term profitability even if top-line growth slows, giving management room to fix operational inefficiencies without destroying shareholder returns.
Management AlignmentInsider buying signals management confidence and alignment with shareholders, improving governance incentives. This long-term alignment can support disciplined capital allocation, steadier strategic execution, and greater credibility with investors and partners.
Bears Say
Declining RevenueSustained top-line contraction undermines scale economics and market positioning. Persistent revenue decline reduces leverage over fixed costs, pressures unit economics, and complicates investments in product development and commercial expansion needed to restore growth.
Weak Cash GenerationSeverely deteriorated cash conversion and negative free cash flow growth signal structural cash generation problems. This threatens liquidity, constrains reinvestment and forces reliance on external financing, which can dilute equity or limit strategic options over the medium term.
Operational Profitability IssuesNegative EBIT margin points to core operating inefficiencies or elevated operating expenses that optional one-offs don't fully explain. If persistent, this undermines sustainable operating earnings and raises execution risk for converting gross margin into durable operating cash flows.
Omega Diagnostics News
CNSL FAQ
What was Omega Diagnostics Group PLC’s price range in the past 12 months?
Omega Diagnostics Group PLC lowest share price was 1.70 p and its highest was 4.33 p in the past 12 months.
What is Omega Diagnostics Group PLC’s market cap?
Omega Diagnostics Group PLC’s market cap is £4.40M.
When is Omega Diagnostics Group PLC’s upcoming earnings report date?
Omega Diagnostics Group PLC’s upcoming earnings report date is Jul 29, 2026 which is in 112 days.
How were Omega Diagnostics Group PLC’s earnings last quarter?
Omega Diagnostics Group PLC released its earnings results on Nov 10, 2025. The company reported 0 p earnings per share for the quarter, the consensus estimate of N/A by 0 p.
Is Omega Diagnostics Group PLC overvalued?
According to Wall Street analysts Omega Diagnostics Group PLC’s price is currently Overvalued.
Does Omega Diagnostics Group PLC pay dividends?
Omega Diagnostics Group PLC does not currently pay dividends.
What is Omega Diagnostics Group PLC’s EPS estimate?
Omega Diagnostics Group PLC’s EPS estimate is >-0.01.
How many shares outstanding does Omega Diagnostics Group PLC have?
Omega Diagnostics Group PLC has 237,950,650 shares outstanding.
What happened to Omega Diagnostics Group PLC’s price movement after its last earnings report?
Omega Diagnostics Group PLC reported an EPS of 0 p in its last earnings report, expectations of N/A. Following the earnings report the stock price went down -15.094%.
Which hedge fund is a major shareholder of Omega Diagnostics Group PLC?
Currently, no hedge funds are holding shares in GB:CNSL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Omega Diagnostics Group PLC
Cambridge Nutritional Sciences plc, through its subsidiaries, develops, manufactures, and distributes medical diagnostics products for the food sensitivity testing market. The company is involved in the research, development, and production of kits for detection of immune reactions to food under the Foodprint name. It provides clinical analysis to the general public, clinics, and health professionals, as well as supplies Food Detective, a consumer food test. The company serves government, private hospitals, reference laboratories, nutritionists, naturopaths, and other healthcare professionals. Cambridge Nutritional Sciences plc operates in the United Kingdom, rest of Europe, North America, South/Central America, India, other Asian countries and the Far East, Africa, and the Middle East. The company was formerly known as Omega Diagnostics Group PLC and changed its name to Cambridge Nutritional Sciences plc in September 2023. Cambridge Nutritional Sciences plc was founded in 1987 and is based in London, the United Kingdom.
Technical Analysis
Advanced Medical Solutions
―
EKF Diagnostics Holdings
―
IXICO plc
―
Tristel
―
Abingdon Health PLC
―
Options Prices
Currently, No data available
---